Brainstorm Cell Therapeutics to Enroll Patients for Study

Brainstorm Cell Therapeutics, a developer of adult stem cell technologies, said it signed a deal with the University of California Irvine Medical Center (UCI) to enroll patients in a planned phase 3 clinical trial of NurOwn in amyotrophic lateral sclerosis (ALS). Shares jumped more than 3.5% in Tuesday’s pre-market.

The move is pending approvals from the Food and Drugs Administration and Institutional Review Board, according to a statement. Namita Goyal has been named the principal investigator at the UCI, which is the third medical center to have entered into an agreement with Brainstorm for the planned study. “NurOwn is a very promising treatment with compelling phase 2 data in patients with ALS,” UCI’s Goyal said. “We look forward to further advancing it in clinical development and confirming the therapeutic benefit with Brainstorm.”

By Celina Yao